

ARTICLE

Detection of classical 17p11.2 deletions, an atypical deletion and *RAI1* alterations in patients with features suggestive of Smith–Magenis syndrome

Gustavo H Vieira^{1,2}, Jayson D Rodriguez¹, Paulina Carmona-Mora³, Lei Cao⁴, Bruno F Gamba², Daniel R Carvalho², Andréa de Rezende Duarte⁵, Suely R Santos⁶, Deise H de Souza², Barbara R DuPont^{1,7}, Katherina Walz^{3,4}, Danilo Moretti-Ferreira^{*2} and Anand K Srivastava^{*1,7}

Smith–Magenis syndrome (SMS) is a complex disorder whose clinical features include mild to severe intellectual disability with speech delay, growth failure, brachycephaly, flat midface, short broad hands, and behavioral problems. SMS is typically caused by a large deletion on 17p11.2 that encompasses multiple genes including the retinoic acid induced 1, *RAI1*, gene or a mutation in the *RAI1* gene. Here we have evaluated 30 patients with suspected SMS and identified SMS-associated classical 17p11.2 deletions in six patients, an atypical deletion of ~139 kb that partially deletes the *RAI1* gene in one patient, and *RAI1* gene nonsynonymous alterations of unknown significance in two unrelated patients. The *RAI1* mutant proteins showed no significant alterations in molecular weight, subcellular localization and transcriptional activity. Clinical features of patients with or without 17p11.2 deletions and mutations involving the *RAI1* gene were compared to identify phenotypes that may be useful in diagnosing patients with SMS.

European Journal of Human Genetics (2012) 20, 148–154; doi:10.1038/ejhg.2011.167; published online 7 September 2011

Keywords: Smith–Magenis syndrome; 17p11.2; *RAI1*; arrayCGH; mutation; deletion

INTRODUCTION

Smith–Magenis syndrome (SMS, MIM 182290) is a multiple congenital anomalies and intellectual disability syndrome associated with a deletion of chromosome 17p11.2. The incidence of SMS is estimated to be ~1:15 000–1:25 000 births.¹ SMS is most commonly characterized by a variable degree of intellectual disability including speech and motor delay, craniofacial and skeletal anomalies, sleep disturbance, self-injurious and attention-seeking behaviors.^{1,2} Craniofacial features include brachycephaly, midface hypoplasia, tented upper lip, relative prognathism with age and deep-set and hypoteloric eyes.^{3,4} Skeletal features include brachydactyly, short stature and short/broad hands.^{3,4} The behavioral phenotype includes onychotillomania, polyembolokoilomania, ‘hand licking and page flipping’, ‘self-hugging’ and hyperactivity.⁵ Sleep disturbance is present in 88% of SMS patients and is characterized by difficulty getting to sleep, frequent nocturnal awakenings, early sleep offset and daytime sleepiness with a need for daytime naps.^{6,7} SMS clinical features overlap with other intellectual disability syndromes such as Prader–Willi, Williams and Down’s syndromes, which often complicate its clinical diagnosis.

A majority, ~90%, of SMS patients have a deletion of chromosome 17p11.2 that includes the *RAI1* gene.³ The classical SMS deletions span ~3.5 Mb of 17p11.2 and are present in ~70% of affected individuals.^{3,8,9} Atypical (smaller or larger) deletions, including the 17p11.2 band, occur in ~20% of other affected individuals.^{3,8,9} Mutations in

the *RAI1* gene have been observed in ~10% of all reported SMS patients.^{10–14}

To date, little is known about the function of human *RAI1*. *RAI1* appears to be a nuclear protein and exhibits transcription factor activity.¹⁵ The transcription factor activity of *RAI1* has been linked to its N-terminal half and the C-terminal half directs it to the nucleus.¹⁵ However, all SMS-associated missense mutations analyzed till date did not produce proteins that differed from the wild-type *RAI1* protein either in their subcellular localization or in their transcription factor activity function,^{15,16} suggesting that there are other essential *RAI1* functions related with the SMS clinical phenotype. A functional network module for SMS has been suggested based on a genome-wide gene expression study using *RAI1* haploinsufficient HEK293T cells.¹⁷

We have analyzed 30 patients of Brazilian origin that were clinically suspected to have SMS. Fluorescence *in situ* hybridization (FISH) analyses revealed six patients with a classical 17p11.2 deletion. Using arrayCGH analyses, we mapped the approximate locations of the deletion boundaries in these six patients and identified an atypical small deletion of ~139 kb that included exons 1 and 2 of the *RAI1* gene in one additional patient. Mutation screening of the coding region of the *RAI1* gene in the remaining patients identified two patients with novel heterozygous nonsynonymous alterations of unknown significance.

¹JC Self Research Institute of Human Genetics, Greenwood Genetic Center, Greenwood, SC, USA; ²Department of Genetics, University of São Paulo State, Botucatu, SP, Brazil; ³John P Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL, USA; ⁴Dr John T Macdonald Foundation Department of Human Genetics, Miller School of Medicine, University of Miami, Miami, FL, USA; ⁵Institute for Integrative Medicine Professor Fernando Figueira – IMIP, Recife, PE, Brazil; ⁶Department of Genetics and Molecular Biology, Federal University of Rio de Janeiro State, Rio de Janeiro, RJ, Brazil; ⁷Department of Genetics and Biochemistry, Clemson University, Clemson, SC, USA

*Correspondence: Dr AK Srivastava, JC Self Research Institute of Human Genetics, Greenwood Genetic Center, 113 Gregor Mendel Circle, Greenwood, SC 29646, USA. Tel: +1 864 388 1806; Fax: +1 864 388 1808; E-mail: anand@ggc.org or Dr D Moretti-Ferreira, Department of Genetics, University of São Paulo State, Botucatu, SP, Brazil. Tel/Fax: +55 14 3811 6229; E-mail: sag@fmb.unesp.br

Received 10 November 2010; revised 7 June 2011; accepted 30 June 2011; published online 7 September 2011

MATERIALS AND METHODS

Subjects

The study was approved by the Research Ethics Committee of Botucatu Medical School, São Paulo State University/UNESP, Brazil. A standardized clinical data collection form was used. A total of 30 patients suspected of having SMS were ascertained from different clinical centers and included in this study using a predetermined inclusion/exclusion criteria. The inclusion criteria were the presence of at least three craniofacial/skeletal muscle system abnormalities, at least one of specific behavior stereotypes, presence or history of sleep disturbance, and presence or history of at least one self-injurious behavior. The exclusion criteria were suspicion/diagnosis of another genetic disease, severe malformation of the central nervous system, a perinatal injury or clinical status compatible with cerebral palsy, and insufficient information on the study inclusion criteria.

The frequency of clinical features from this study (Table 1) and the frequency described in the literature were compared. Statistical analysis was performed using the two-tailed Fisher's exact test.

Fluorescence *in situ* hybridization (FISH)

Metaphase chromosome spreads were obtained from lymphoblasts from patients using the conventional methods. FISH was performed using commercial probes with the *RAI1* gene (catalog # LPU019, Cytoecell, Cambridge, UK) as the target. The probe was 160 kb in size and includes the distal region of the *RAI1* gene (D175258). Metaphase analyses were performed using a fluorescence microscope (Leitz DM RBE – LEICA, Wetzlar, Germany).

Whole-genome array CGH and quantitative PCR (qPCR)

Genomic DNA was purified using the Wizard Genomic DNA Purification Kit (Promega, Sunnyvale, CA, USA). Patient DNA was labeled, hybridized to an Affymetrix Genome Wide Human SNP Nsp/Sty 6.0 array and washed according to the manufacturer's protocol (Affymetrix, Santa Clara, CA, USA). Data quality was assessed using the Birdseed v2 algorithm (Broad Institute, Cambridge, MA, USA). Signal intensity and copy number status for each probe set was extracted using Affymetrix Genotyping Console Version 4.0 software. Changes in copy number were confirmed by qPCR using iQ SYBR Green Supermix on a CFX96 Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA) as described previously.¹⁸ Data were analyzed with CFX Manager Software (Bio-Rad).

Mutation screening

The entire coding region and up to 100 bp of flanking intronic sequences of the *RAI1* gene were amplified by standard PCR. Amplified products were treated with ExoSAP-IT (USB Corporation, Cleveland, OH, USA), bidirectionally sequenced by the Sanger method using the BigDye Terminator v3.1 Cycle Sequencing Kit and separated on an ABI 3730xl DNA analyzer (Applied Biosystems, Carlsbad, CA, USA). Primer sequences and reaction mixes are available on request. Sequences were analyzed with DNASTAR SeqMan II software (Madison, WI, USA).

Plasmid constructs

The full-length clone of human *RAI1*-HA cDNA was generated previously.¹⁵ The variant *RAI1*-HA R1217Q was generated using the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA) utilizing the primers forward: 5'-GCTCTCTGACCAGCCCCCTCCATG-3' and reverse: 5'-CATGAGGGGGCTGGTCAGAGAGC-3'. The variant *RAI1*-HA Q1389R was generated by overlapping PCR. The following primers were used: forward 1: 5'-GGAGACAGACTCACCCAGCACG-3', reverse 1: 5'-GGAGCTTCCGCCCCG GTG-3', forward 2: 5'-CACCGGGCGGAAGCTCC-3' and reverse 2: 5'-GCG GGCCTTTGGAGAGTCCATG-3'. The mutated fragments were subcloned to replace the wild-type sequence into full-length *RAI1* cDNA with the enzymes *AfeI* and *PflMI*. All clones were verified by DNA sequencing for the presence of the desired variation and no extra changes in the nucleotide sequence. Wild-type *RAI1* and the variant proteins contain the influenza virus hemagglutinin epitope tag (HA) at the C-terminal end to facilitate their detection. For expression analysis, the cDNAs of *RAI1* wild-type and mutant forms were subcloned into pALTER-MAX vector (Promega).

Immunofluorescence and western blot analysis

Neuro-2a cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, penicillin (100 units/ml) and

streptomycin (100 µg/ml) at 37°C with 5% CO₂ until 95% confluence was attained. To study the expression of the *RAI1* proteins, Neuro-2a cells were transfected with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), and the plasmid pALTER-MAX *RAI1*-HA wild-type, *RAI1*-HA R1217Q or *RAI1*-HA Q1389R. All transfections were performed according to the manufacturer's protocols described previously.¹⁵

For immunofluorescence, cells were fixed 24 h after transfection with 4% paraformaldehyde followed by permeabilization with 0.2% Triton X-100 in phosphate-buffered saline. Subcellular localization of *RAI1*-HA wild-type and mutant forms were detected using the anti-HA high-affinity antibody (1:1000, clone 3F10, Roche, Indianapolis, IN, USA). Secondary antibody conjugated to Alexa fluor 488 (1:1000, Invitrogen) was used. Cells were stained with 4',6-diamidino-2-phenylindole, dihydrochloride (DAPI) and mounted with Dako fluorescent mounting medium.

For western blot analysis, total protein extracts were prepared 24 h after transfection. Cells were lysed in 100 µl of protein extraction and loading buffer (2% SDS, 2 M urea, 10% glycerol, 10 mM Tris pH 6.8, 0.002% bromophenol blue and 10 mM DTT) plus 1:200 protease inhibitor cocktail (Sigma, St Louis, MO, USA). The samples were homogenized by passing them 20 times through a syringe and incubated at 95°C for 5 min. Approximately, 20 µl of each cell lysate was loaded onto 4–20% SDS-polyacrylamide gels with Tris/glycine running buffer and transferred to a 0.2 µm poly-vinylidene fluoride (PVDF, Bio-Rad Laboratories) membrane. Immunodetection was performed using rat anti-HA (1:7000, Roche) and rabbit anti-β-tubulin (1:1000, sc-9104 Santa Cruz, Santa Cruz, CA, USA). Results were visualized by chemiluminescence.

Reporter gene assays

Transient transfections in Neuro-2a cells were performed in 35-mm plates. The amounts of plasmid DNA used were determined according to the manufacturer's protocol. GAL4-BD fusions of human *RAI1* wild-type and its mutant forms were co-transfected with the luciferase reporter plasmid pFR-Luc (Agilent Technologies). For normalizing the results in case of transfection efficiency variations, the vector pSV-β-galactosidase (Promega Corporation) was also co-transfected for expression of β-galactosidase. After 48 h post-transfection, the cells were lysed and the luciferase activity was measured using the Luciferase Assay Kit (Agilent Technologies) according to the manufacturer's instructions. The relative lights units (RLUs) were measured in duplicate in a luminometer (Turner Biosystems 20/20n, Promega Corporation).

The β-galactosidase activity of the extracts was measured using the micro-assay protocol of β-galactosidase Assay kit (Agilent Technologies). Each cell assay was carried out in duplicate.

RESULTS

We have analyzed a cohort of 30 Brazilian patients with clinical features suggestive of SMS to determine if their clinical features are because of a defect in the SMS causative gene, *RAI1*. These patients have some of the features typically seen in patients with SMS. For example, typical facies (brachycephaly, midface hypoplasia and 'tenting' upper lip), intellectual disability, sleep disturbance, hypotonia, speech delay, and characteristic SMS behaviors (self-injury, self-hugging and aggression; Table 1).

FISH, whole-genome array CGH and qPCR analyses

FISH analysis using commercial probes with the *RAI1* gene as the target revealed deletions at chromosome 17p11.2, in six patients (data not shown). Whole-genome arrayCGH was performed to determine the size and breakpoints of the deletions. This analysis confirmed all six 17p11.2 deletions and determined that the deletions were ~3.61–3.67 Mb in sizes (Figure 1a). Additionally, an atypical deletion of 139 kb was identified in one patient (Figure 1b). This deletion included the 5' end of the *RAI1* gene and apparently resulted in the partial loss of the *RAI1* gene (Figure 1b). The coordinates and sizes of all seven deletions are shown in Table 2. Of the 30 patients studied, 7 (23%) had a deletion that included all or part of the *RAI1* gene.

Table 1 Clinical features of SMS and SMS-like groups

	<i>17p11.2 classical deletion, n=6 (a)</i>	<i>17p11.2 small deletion, n=1 (b)</i>	<i>RAI1 variant, n=2 (c)</i>	<i>SMS (a+b+c)^a</i>	<i>SMS-like n=21^b</i>	<i>P-value^c</i>
Age average	16.16	28.00	8.30	14.7	13.4	0.5986
Gender	3M/3F	1M	2M	6M/3F	9M/12F	0.4348
<i>Craniofacial</i>						
Brachycephaly	4/6	0/1	1/2	5/9	8/21	0.4434
Midface hypoplasia	5/5	0/1	1/1	5/7	15/21	0.6391
Broad, square-shaped face	6/6	1/1	1/2	8/9	12/18	0.3748
Deep-set, close-spaced eyes	5/6	0/1	1/2	6/9	11/21	0.6908
Everted, 'tentled' upper lip	6/6	0/1	2/2	8/9	15/21	0.3816
Relative prognathism with age	5/5	0/1	2/2	7/8	12/21	0.2008
Dental anomalies	4/4	0/1	2/2	6/8	7/15	0.1649
<i>Skeletal</i>						
Short broad hands	5/5	1/1	2/2	8/8	8/19	0.0095
Brachydactyly	4/4	—	0/1	4/5	1/11	0.0128
Short stature	5/6	0/1	1/2	6/9	7/18	0.2177
Scoliosis	2/6	1/1	0/1	3/8	9/21	1.0000
<i>Neurological</i>						
Cognitive impairment/developmental delay	6/6	1/1	2/2	9/9	20/21	1.0000
Speech delay	6/6	0/1	2/2	8/9	19/20	0.5320
Motor delay	4/4	—	2/2	6/6	9/9	1.0000
Infantile hypotonia	3/5	0/1	2/2	5/8	16/20	0.3715
Sleep disturbance	4/5	1/1	2/2	7/8	15/18	1.0000
Oral sensorimotor dysfunction	3/3	0/1	1/1	4/5	8/11	1.0000
Hyporeflexia	1/5	0/1	0/1	1/7	5/16	0.6214
Epilepsia	2/6	0/1	1/2	3/9	10/17	0.3999
Generalized complacency/lethargy (infancy)	4/4	0/1	1/1	5/6	9/14	0.6129
<i>Behavior</i>						
Self-hug	5/6	0/1	2/2	7/9	13/21	1.0000
Onychotillomania	3/5	1/1	2/2	6/8	15/20	1.0000
Polyembolokoilomania	4/5	0/1	2/2	6/8	8/19	0.0809
Head banging/face slapping	0/1	1/1	2/2	3/4	6/9	1.0000
Hand biting	3/4	0/1	2/2	5/7	7/10	1.0000
Attention seeking	4/4	1/1	1/1	6/6	11/13	1.0000
Aggressive behavior	5/5	1/1	2/2	8/8	17/20	0.5453
Lick and flip	2/4	1/1	2/2	5/7	8/15	1.0000
Self-injurious behaviors	6/6	1/1	2/2	9/9	18/20	1.0000
Hyperactivity	3/3	1/1	2/2	6/6	4/4	1.0000
<i>Other features</i>						
Hearing loss	2/5	—	—	2/5	3/10	1.0000
Myopia	1/1	—	—	1/1	1/5	0.3333
Strabismus	3/3	—	—	3/3	0/1	0.2500
Iris abnormalities	3/3	—	—	3/3	0/6	0.0119
History of constipation	2/4	1/1	0/1	3/6	9/16	1.0000
Inverted circadian rhythm of melatonin	0/1	1/1	1/1	2/3	6/9	1.0000
Velopharyngeal insufficiency	1/1	0/1	—	1/2	1/7	0.4167
Cardiac defects	0/5	0/1	0/1	0/7	6/14	0.0609
Renal/urinary tract abnormalities	1/2	0/1	—	1/3	2/6	1.0000
Cleft lip/palate	0/5	—	0/2	0/7	0/16	1.0000
Hypogonadism (in males)	1/2	—	1/1	2/3	0/7	0.6670
Obesity	2/4	0/1	0/2	2/7	3/16	0.6214

Abbreviation: SMS, Smith–Magenis syndrome.

Bold type is used for headings and statistically significant *P*-values of <0.05.^adel17p11.2 or RAI1 mutation.^bNo deletion or point mutation.^c*P*-values from two-tailed Fisher's exact tests.




Figure 1 (a) Array CGH profiles of chromosome 17 in six patients with the classical deletion of SMS and schematic representation of chromosome 17p11.2. Representative gene content of the 17p11.2 deletion is shown. The *RAI1* gene is indicated by a red arrow. Other deletions involving the 17p11.2 region described by Elsea and Girirajan³ are shown below. (b) Array CGH profile of chromosome 17 in SAG7567 and schematic representation of the *RAI1* gene transcript. Black bars indicate qPCR amplicons used for confirmation of deletions found by arrayCGH. (c) Analysis by qPCR, which confirmed the occurrence of deletion of exon 3 of the *RAI1* gene in six patients of SMS: PT1 (SAG6339) PT2 (SAG7131), PT3 (SAG7132), PT4 (SAG7571), PT5 (SAG5120) and PT6 (SAG6052), along with normal controls (NL1 and NL2). (d) Analysis by quantitative real-time PCR, which confirmed the occurrence of deletion of exon 2 of the *RAI1* gene in one patient of SMS. The parental samples do not carry the deletion, shown with two normal controls (NL1 and NL2).

To confirm the results obtained by arrayCGH and to identify any additional smaller deletions, all of the SMS group and the SMS-like group of patients were analyzed by qPCR using an amplicon specific to the *RAI1* gene. qPCR and arrayCGH results were consistent (Figure 1c) for all six patients with classical SMS deletions. Interestingly, in the patient of the atypical microdeletion, the results obtained by arrayCGH suggested the deletion ends at or near exon 3 of the *RAI1* gene. However, using primers for the initial and medial portions of exon 3, qPCR determined that exon 3 was not deleted (data not shown). Furthermore, additional qPCR with exon 2 primers confirmed the presence of a *de novo* heterozygous deletion in this patient (Figure 1d).

RAI1 gene mutation screening in patients with no 17p11.2. deletion

Using direct sequencing of the coding region of the *RAI1* gene, we identified two heterozygous nonsynonymous variants in exon 3 of the gene (Figure 2). In patient SAG4739, a c.3650G>A alteration is predicted to cause an amino acid change from a glutamine to an arginine at position 1217 (p.R1217Q, Figure 2a). In patient SAG6888, a c.4166A>G alteration is predicted to cause an arginine to a glutamine substitution at position 1389 (p.Q1389R, Figure 2b). We also identified a new SNP (c.1143C>T; p.A381V) and several previously reported SNPs; allele frequencies of these SNPs in this cohort are shown in Supplementary Table 1.

The two residues involved in the alterations were found to be highly conserved (Figure 2c). Both alterations were absent in 150 control samples including 50 normal Brazilian controls. The pathogenicity of these two alterations remains to be determined and thus these are

considered variants of unknown significance. Bioinformatics analyses were performed using PolyPhen (<http://genetics.bwh.harvard.edu/pph/>), SIFT (<http://sift.bii.a-star.edu.sg/>), PMut (<http://mmb.pcb.ub.es/PMut/>) and Panther (<http://www.pantherdb.org/tools/>). The variant p.R1217Q was predicted to be damaging by Panther, PMut and SIFT but Polyphen suggested this to be a benign change. The variant p.Q1389R was predicted to be pathological or damaging by all four methods. The findings are summarized in Supplementary Table 2.

Functional characterization of nonsynonymous alterations identified in patients with SMS phenotype

To investigate if the two new nonsynonymous changes present in the *RAI1* protein: p.R1217Q. and p.Q1389R alter the molecular weight, subcellular localization or transcription activity function of the *RAI1* protein, we generated both variants (Figure 3a) as described in Materials and methods. To determine the molecular weight of the resulting proteins, *RAI1*-HA, *RAI1*-HA R1217Q and *RAI1*-HA Q1389R clones were transiently transfected and 24 h post-transfection the cell lysates were run in a 4–20% gradient SDS-PAGE gel. As shown in Figure 3b, the molecular weight of both variant proteins is ~260 kDa similar to the wild type.

For both variants, we evaluated the transcription factor activity as performed previously.¹⁵ As shown in Figure 3c, both *RAI1*-HA R1217Q and *RAI1*-HA Q1389R variant proteins showed an increment of 105.2 ± 8.4 and 93.85 ± 10.1 percentage of activation of luciferase activity respectively, when compared with the wild type as 100% (no significant changes for any variant). These data indicate that the variant polypeptides retained the transcription factor capacity. The subcellular localization of the variant proteins was also evaluated, and nuclear localization was found for both variant proteins (Figure 3d,e). Together these results indicate that the *RAI1*-HA R1217Q and *RAI1*-HA Q1389R variants are not affecting the synthesis, transcription factor activity or subcellular localization of the *RAI1* protein.

Clinical characteristics of patients with or without the *RAI1* gene defect

Of 30 patients clinically and molecularly evaluated, 6 had classical deletions (Table 1, column a), 1 had an atypical deletion (Table 1, column b) and 2 showed nonsynonymous alterations in the *RAI1* gene (Table 1, column c). Clinical features of these patients are summarized in Table 1. All nine patients showed some intellectual disability and

Table 2 17p11.2 Copy number variation identified in the SMS cohort

Patient (no.) ^a	Start (bp)	End (bp)	Size (Mb)
SAG6339	16 658 950	20 336 467	3.67
SAG7131	16 714 862	20 325 512	3.61
SAG7132	16 676 257	20 325 512	3.64
SAG7571	16 712 991	20 336 467	3.62
SAG5120	16 697 860	20 325 512	3.62
SAG6052	16 714 862	20 336 467	3.62
SAG7567	17 507 060	17 645 576	0.14

Abbreviation: SMS, Smith–Magenis syndrome.




Figure 2 Automated sequence chromatograms showing *RAI1* variants in patients. Triplet codon (underlined) and translated amino acids are shown. The two *RAI1* gene heterozygous variations, (a) a c.3650G>A (p.R1217Q) in patient SAG4739 and (b) a c.4166A>G (p.Q1389R) in patient SAG6888 are shown. (c) Alignment of selected region of human *RAI1* showing residues (in bold types) altered in patients that are conserved in other mammals.




Figure 3 *In vitro* evaluation of two point mutations associated with SMS. (a) Schematic representation of RAI1-HA, RAI1-HA R1217Q and RAI1-HA Q1389R. In blue is represented the poly-Gln domain, in yellow: poly-Ser domains, the *in silico* described nuclear localization signals are depicted in black, in slanted line: the PHD domain. The coding sequence for HA epitope is represented in red. Both generated mutants were confirmed by DNA sequencing (data not shown). (b) The molecular weight of mutated proteins was calculated by western blot analysis with anti-HA antibody in Neuro-2a cells extracts. The obtained molecular weight is depicted and also the controls for the immunoreactivity are shown (e/v, extracts transfected only with the empty vector and u/t represents untransfected cells control). Anti-β-tubulin was used as a loading control. (c) The percentage of the reporter transcription activation is shown for RAI1-HA R1217Q (white) and RAI1-HA Q1389R (gray) compared with RAI1-HA wild-type protein (black). Values represent mean ± SEM. (d) Each plasmid was transfected in Neuro-2a cells and immunofluorescence was performed with anti-HA (green) antibody, whereas nuclei staining is shown with DAPI. (e) The subcellular localization of 200 positive cells for the immunodetection is summarized. α, Antibody against.

behavior disturbance, with self-injurious behavior and hyperactivity most frequently noted. Facial phenotypes of patients with a classical deletion, an atypical deletion and an *RAI1* point mutation and from the SMS-like group are shown in Figure 4. The frequencies of characteristic features in all nine patients (Table 1, column a+b+c) are compared with the frequency of common SMS features analyzed by Edelman *et al.*¹⁹ For clinical comparison, nine patients with the 17p11.2 deletion or a *RAI1* mutation were classified as the SMS group (Table 1, a+b+c) and the other 21 patients with some clinical features of SMS, but no chromosome 17p11.2 deletion or a *RAI1* mutation were classified as the 'SMS group' and the 'SMS-like group', as suggested previously.²⁰ No statistical differences were noted except for short broad hands, brachydactyly and iris abnormalities (Table 1).

DISCUSSION

SMS is a contiguous gene deletion syndrome associated with multiple physical anomalies, intellectual disability, sleep disturbance and stereotypical behaviors. This combination of traits is associated with a heterozygous deletion at chromosome 17p11.2. Clinical and molecular analyses were performed to evaluate 30 patients suspected of having SMS. The evaluated patients had a broad range of phenotypes, with some characteristics typical of SMS (Table 1). More than 90% of the patients in this study had intellectual disability, delayed speech-language development and self-injurious behavior. Our findings showed that 30% (9/30) had a deletion in the 17p11.2 region or a point mutation in the *RAI1* gene. Within this group, we found that 66% (6/9) carried a classic deletion, 11% (1/9) had an atypical deletion and 22% (2/9) had a missense alteration in the *RAI1* gene. These data are similar to the proportion previously described by Vlangos *et al.*⁹

Normally, the primary transcript of the *RAI1* gene is transcribed from exons 3, 4, 5 and part of exon 6. An atypical *de novo* deletion in

one patient caused a loss of the noncoding exon 2, but not of the coding exons. Interestingly, the deleted region is relatively rich in CpG islands¹¹ and thus an impact on transcription regulation of the *RAI1* gene is speculated. Unfortunately, analyses to examine the *RAI1* gene transcript were not possible because cultured cells from the patient were not available. To our knowledge, this is the first report of a partial deletion of the *RAI1* gene in SMS group of patients.

In the six patients that showed a classic SMS deletion, the breakpoints were recurrent and coincided with the regions described as proximal SMS-REP and distal SMS-REP.¹² This fact supports the idea that, in these classic patients, the deletion mechanism may be the erroneous alignment of low copy repeats (LCR), generating a deleterious nonallelic homologous recombination.

Finally, we screened for alterations in exons 3, 4, 5 and the coding portion of exon 6 (primary transcript) of the *RAI1* gene in 24 patients. These were the 23 patients in whom no deletions were found in the 17p11.2 region plus the single patient who showed a partial deletion of the *RAI1* gene. There are currently 15 reported mutations that have been described in the *RAI1* gene.^{10–14} We have identified two additional nonsynonymous variants (p.R1217Q, p.Q1389R). The alterations are not located in RAI1 functional domains, but the substituted amino acids have different physical characteristics. One variant, p.Q1389R, was predicted to be pathological or damaging. However, bioinformatic analyses (Supplementary Table 2) did not suggest unequivocally pathological nature for variant p.R1217Q. *In vitro* functional analyses showed no abnormal molecular weight, subcellular localization or transactivational activity for any of these mutants, suggesting that they may be implicated in the association with other proteins or some other functional role of RAI1 that is not known to date, but fundamental to the SMS clinical phenotype. Further analyses of both variants in ethnically matched normal controls are warranted.




Figure 4 Facial features of patients with (a) a classical deletion (SAG6052), (b) an atypical deletion (SAG7567), (c) a nonsynonymous variant, p.R1217Q (SAG4739) and (d) a patient from the SMS-like group, with no known alteration.

When patients are separated into groups of SMS (9 patients) or SMS-like individuals (21 patients), there were no statistical differences apparent in the distributions of age or gender (data not shown). When craniofacial and skeletal features were analyzed, only the features ‘small and broad hands’ and ‘brachydactyly’ were more frequent in the SMS group. There were no significant statistical differences between groups in the frequency of otorhinolaryngological, neurological and behavioral features. Iris abnormalities were reported in 30% of patients and it was the only feature with a significant statistical difference (between SMS and SMS-like groupings) among those less frequently reported in patients with SMS. In the study by Williams *et al*,²⁰ ocular anomalies and brachydactyly also showed significant statistical differences. However, differences described by Williams *et al*,²⁰ such as stereotypical behavior, seizures, craniofacial anomalies, ear infections, cleft lip and palate, hoarse voice, cardiac defects, digestive problems and short stature were not noted in this study. The analysis of the clinical data corroborated the idea that there are very similar phenotypes among patients with a 17p11.2 deletion and those with a mutation in the *RAI1* gene.^{10,20,21}

No obvious deletions or duplications were noted in the 21 SMS-like patients in this study. However, recently we have reported a female patient with a deletion at chromosome 1p36.32–1p36.33 and with overlapping clinical symptoms of the 1p36 deletion syndrome and SMS.²² Interestingly, Williams *et al*²⁰ found monosomy of at least five different autosomal regions including one at 1p36.3 in patients with SMS-like phenotype without a deletion or mutation in the *RAI1* gene.²⁰ These findings point to the involvement of other genes that likely contribute to SMS or SMS-like phenotype.^{20,22}

We conclude that phenotypic similarity exists among patients with deletions in the 17p11.2 region or mutations in the *RAI1* gene (SMS group) and patients with only a few features of the SMS phenotype (SMS-like group). Our findings add information toward the etiology of SMS and may facilitate a better diagnosis of SMS.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We are grateful to the patients and the parents for participation in this study. We thank Cindy Skinner, Lynn Dukes-Rimsky, Raewyn Lowe, Melissa Cook, Julianne Collins and Carlos Eduardo Frigério Domingues for providing assistance at various stages of this study. We thank Sarah H Elsea for sharing *RAI1* gene primer sequences. This study was supported in part by funds from the SC Department of Disabilities and Special Needs, a fund from the Coordination for the Improvement of Higher Education Personnel (CAPES) foundation, Brazil to GHV, and a fund from the Jerome Lejeune Foundation to KW.

- Greenberg F, Guzzetta V, Montes de Oca-Luna R *et al*: Molecular analysis of the Smith-Magenis syndrome: a possible contiguous-gene syndrome associated with del(17)(p11.2). *Am J Hum Genet* 1991; **49**: 1207–1218.
- Smith ACM, Magenis RE, Elsea SH: Overview of Smith-Magenis syndrome. *J Assoc Genet Technol* 2005; **31**: 163–167.
- Elsea SH, Girirajan S: Smith-Magenis syndrome. *Eur J Hum Genet* 2008; **16**: 412–421.
- Smith ACM, Boyd K, Elsea SH *et al*: Smith-Magenis Syndrome; in: *GeneReviews at GeneTests: Medical Genetics Information Resource (database online)*. Seattle: Copyright, University of Washington, 1997–2010.
- Dykens EM, Finucane BM, Gayley C: Brief report: cognitive and behavioral profiles in persons with Smith-Magenis syndrome. *J Autism Dev Disord* 1997; **27**: 203–211.
- De Leersnyder H, de Blois MC, Vekemans M *et al*: beta(1)-adrenergic antagonists improve sleep and behavioural disturbances in a circadian disorder, Smith-Magenis syndrome. *J Med Genet* 2001; **38**: 586–590.
- Smith AC, Dykens E, Greenberg F: Sleep disturbance in Smith-Magenis syndrome (del 17 p11.2). *Am J Med Genet* 1998; **81**: 186–191.
- Potocki L, Shaw CJ, Stankiewicz P *et al*: Variability in clinical phenotype despite common chromosomal deletion in Smith-Magenis syndrome (del(17)(p11.2p11.2)). *Genet Med* 2003; **5**: 430–434.
- Vlangos CN, Yim DK, Elsea SH: Refinement of the Smith-Magenis syndrome critical region to approximately 950 kb and assessment of 17p11.2 deletions. Are all deletions created equally? *Mol Genet Metab* 2003; **79**: 134–141.
- Slager RE, Newton TL, Vlangos CN *et al*: Mutations in *RAI1* associated with Smith-Magenis syndrome. *Nat Genet* 2003; **33**: 466–468.
- Bi W, Saifi GM, Shaw CJ *et al*: Mutations of *RAI1*, a PHD-containing protein, in nondeletion patients with Smith-Magenis syndrome. *Hum Genet* 2004; **115**: 515–524.
- Bi W, Saifi GM, Girirajan S *et al*: *RAI1* point mutations, CAG repeat variation, and SNP analysis in non-deletion Smith-Magenis syndrome. *Am J Med Genet A* 2006; **140**: 2454–2463.
- Girirajan S, Elsas LJ, Devriendt K *et al*: *RAI1* variations in Smith-Magenis syndrome patients without 17p11.2 deletions. *J Med Genet* 2005; **42**: 820–828.
- Truong HT, Dudding T, Blanchard CL *et al*: Frameshift mutation hotspot identified in Smith-Magenis syndrome: case report and review of literature. *BMC Med Genet* 2010; **11**: 142.
- Carmona-Mora P, Encina CA, Canales CP *et al*: Functional and cellular characterization of human Retinoic acid induced 1 (*RAI1*) mutations associated with Smith-Magenis Syndrome. *BMC Mol Biol* 2010; **11**: 63.
- Carmona-Mora P, Walz K: Retinoic acid induced 1, *RAI1*: a dosage sensitive gene related to neurobehavioral alterations including autistic behavior. *Curr Genomics* 2010; **11**: 607.
- Girirajan S, Truong HT, Blanchard CL, Elsea SH: A functional network module for Smith-Magenis syndrome. *Clin Genet* 2009; **75**: 364–374.
- Griggs BL, Ladd S, Decker A *et al*: Identification of ectodysplasin-A receptor gene deletion at 2q12.2 and a potential autosomal MR locus. *Eur J Hum Genet* 2009; **17**: 30–36.
- Edelman EA, Girirajan S, Finucane B *et al*: Gender, genotype, and phenotype differences in Smith-Magenis syndrome: a meta-analysis of 105 cases. *Clin Genet* 2007; **71**: 540–550.
- Williams SR, Girirajan S, Tegay D *et al*: Array comparative genomic hybridisation of 52 subjects with a Smith-Magenis-like phenotype: identification of dosage sensitive loci also associated with schizophrenia, autism, and developmental delay. *J Med Genet* 2010; **47**: 223–229.
- Toulouse A, Rochefort D, Roussel J *et al*: Molecular cloning and characterization of human *RAI1*, a gene associated with schizophrenia. *Genomics* 2003; **82**: 162–171.
- Vieira G, Rodriguez JD, Boy R *et al*: Differential diagnosis of Smith-Magenis syndrome: 1p36 deletion syndrome. *Am J Med Genet A* 2011; **155**: 988–992.

Supplementary Information accompanies the paper on European Journal of Human Genetics website (<http://www.nature.com/ejhg>)